Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;39(7):3727-3737.
doi: 10.21873/anticanres.13521.

Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer

Nguyen Linh Toan  1 , Ngo Thu Hang  2   3 , Nguyen Kim Luu  4 , Can VAN Mao  2 , Nguyen VAN Ba  4 , Nguyen Thi Xuan  5 , Truong Dinh Cam  6 , Naoki Yamamoto  7 , Hoang VAN Tong  2   8 , Ho Anh Son  1   8
Affiliations

Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer

Nguyen Linh Toan et al. Anticancer Res. 2019 Jul.

Abstract

Background/aim: This study aims to investigate whether the combination of oncolytic viruses with chemoradiotherapy or other therapies is a promising strategy for cancer treatment.

Materials and methods: The anticancer effects of measles virus (MeV) in combination with nimotuzumab in the treatment of laryngeal cancer were evaluated in vitro and in nude mice inoculated with Hep2 tumors. MTT assay and flow cytometry were used to examine cell death.

Results: Laryngeal cancer cells treated with MeV+nimotuzumab combination had a significantly lower survival rate compared to those treated with MeV or nimotuzumab alone (p<0.0001). In an animal model bearing human laryngeal tumor, the treated group had a higher survival rate (60%) compared to a untreated group (20%) (p<0.05), and the survival rate of the group treated with MeV+nimotuzumab combination was higher compared to the groups received single treatment.

Conclusion: The MeV+nimotuzumab combination has greater anticancer activities in both laryngeal cancer cells and an animal model.

Keywords: Measles virus; Oncolytic virus; cancer target; laryngeal cancer; monoclonal antibody; nimotuzumab.

PubMed Disclaimer